Precision medicine takes center stage at ILD Day 2026

This September 16, 13 patient advocacy and research organizations are uniting for the sixth annual ILD Day — and this year's spotlight is on precision medicine. A free webinar at 1 p.m. ET will bring together healthcare professionals, patients, and caregivers to explore how biology-based approaches are beginning to transform care for the diverse group of conditions that fall under interstitial lung disease (ILD).

Amy Hajari Case, MD, chief medical officer of the Pulmonary Fibrosis Foundation, says precision medicine is the future of ILD care — and the parallels to oncology are striking. Just as cancer treatment now hinges on molecular markers rather than histology alone, the hope is that genomics, biomarkers, and radiomics will one day guide ILD treatment decisions with the same precision.

Key Takeaways:

• The PRECISIONS project has advanced understanding of molecular and genetic distinctions across ILD subtypes, informing future therapeutic strategies
• Clinicians are already practicing personalized ILD care by factoring in disease severity, comorbidities, and individual patient characteristics
• Patients are encouraged to join research registries like the PFF Registry and clinical trials to help accelerate discovery

Why it matters: ILD encompasses a wide range of conditions — from sarcoidosis to rheumatoid arthritis-associated lung disease — that don't always fit neatly under the "pulmonary fibrosis" umbrella. Precision medicine offers a path toward better diagnosis, prognosis, and treatment matching for this underserved and heterogeneous patient population.